Engineered immune cells take aim at Hard-to-Treat cancers
NCT ID NCT05672459
First seen Jan 30, 2026 · Last updated Apr 25, 2026 · Updated 10 times
Summary
This early-stage trial tests a new treatment called IVS-3001, which uses a patient's own immune cells (CAR-T cells) that are modified to recognize and attack a protein called HLA-G found on some solid tumors. The study includes 31 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the safety of the therapy and see if it can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.